These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24840258)

  • 1. Best Practice & Research Clinical Endocrinology & Metabolism. Pharmacological treatment of dyslipidaemias. Preface.
    Rubenfire M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):279. PubMed ID: 24840258
    [No Abstract]   [Full Text] [Related]  

  • 2. [ESC/EAS Guidelines for the management of dyslipidaemias].
    Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
    Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
    [No Abstract]   [Full Text] [Related]  

  • 3. The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids.
    Roberts WC; Gotto AM; Guyton J; LaRosa J; Viggiani R
    Am J Cardiol; 2011 Jan; 107(2):230-42. PubMed ID: 21211600
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alternative drugs to statins].
    Scheen AJ
    Rev Prat; 2011 Oct; 61(8):1121-2. PubMed ID: 22135982
    [No Abstract]   [Full Text] [Related]  

  • 5. Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor.
    Vincent J
    Clin Pharmacol Ther; 2014 Jul; 96(1):3-7. PubMed ID: 24942393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 7. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations.
    Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212
    [No Abstract]   [Full Text] [Related]  

  • 8. Reflections on a pioneer in the field of diet, lipids and vascular disease.
    Packard CJ
    Atherosclerosis; 2015 Dec; 243(2):656-7. PubMed ID: 26522437
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of dyslipidaemias.
    Paramsothy P; Knopp R
    Heart; 2006 Oct; 92(10):1529-34. PubMed ID: 16973811
    [No Abstract]   [Full Text] [Related]  

  • 10. [Statement on new modern hypolipidemic therapy].
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2015 Nov; 61(11):933-5. PubMed ID: 26946544
    [No Abstract]   [Full Text] [Related]  

  • 11. New ESC/EAS Guidelines for the management of dyslipidaemias - any controversies behind the consensus?
    Reiner Z
    Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):724-7. PubMed ID: 21945917
    [No Abstract]   [Full Text] [Related]  

  • 12. Current lipid-modifying agents.
    Agouridis AP; Filippatos TD; Katsiki N
    Expert Opin Pharmacother; 2015 May; 16(7):1117-8. PubMed ID: 25845932
    [No Abstract]   [Full Text] [Related]  

  • 13. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of dyslipidemia in 2014: European versus American guidelines].
    Radermecker RP
    Rev Med Suisse; 2014 Aug; 10(439):1534-7. PubMed ID: 25272669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of scientific production for the political consolidation of professional practice.
    Queiroga BA; Moura MC; Pazini S; Zorzi J
    Codas; 2016 Apr; 28(2):91-2. PubMed ID: 27191869
    [No Abstract]   [Full Text] [Related]  

  • 16. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 17. Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?
    Elis A
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):675-7. PubMed ID: 22894621
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.